In accordance to Article 6 of the “Regulations Governing the Scope of Material Information and the Means of its Public Disclosure Under Article 157-1, Paragraphs 5 and 6 of the Securities and Exchange Act”, Adimmune uploands all relevant information that would have a material impact on its stock price or on the investment decisions of a reasonably prudent investor, and that will have a material impact on the ability of the company to pay principal or interest into the Market Observation Post System for public disclosure.